[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-405232-105":59,"doc-detail-405232-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","long-acting-injectable-lai-prep-implementation-guide-dosing-labs-and-workflow","Long-Acting Injectable (LAI) PrEP Implementation Guide - Dosing, Labs, and Workflow","","Long-Acting Injectable (LAI) PrEP Implementation Guide compares CAB-LA and LEN regimens, detailing administration routes, initiation and maintenance schedules, and optional oral lead-in requirements. It outlines handling of missed or delayed injections, including HIV bridging options and when to resume or repeat initiation dosing. The guide specifies baseline and follow-up laboratory testing by drug, counseling points for protection timelines, follow-up visit expectations, drug-interaction review, and considerations for building clinical workflows, reminders, and benefit navigation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-acting-injectable-lai-prep-implementation-guide-dosing-labs-and-workflow/405232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-acting-injectable-lai-prep-implementation-guide-dosing-labs-and-workflow/405232.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do CAB-LA and LEN differ in dosing frequency and injection schedule?","Question",{"text":113,"@type":114},"CAB-LA is administered as an IM injection every 2 months (1 injection per visit). LEN is given as SC injections every 6 months (2 injections per visit).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What should be done if LAI PrEP injections are delayed?",{"text":118,"@type":114},"If delays are anticipated, offer oral PrEP as interim bridging. For CAB-LA, HIV testing is recommended when oral bridging is not used for more than 7 days, and injections are resumed based on the last injection timing; for LEN, repeat initiation with an oral lead-in is recommended if too much time has passed since the last injection.",{"name":120,"@type":111,"acceptedAnswer":121},"What laboratory tests are required at baseline and during follow-up for patients on LAI PrEP?",{"text":122,"@type":114},"Baseline and follow-up HIV testing are required at injection appointments, with lab-based Ag/Ab and, for CAB-LA, HIV RNA testing using blood samples. Additional baseline screening includes HAV/HBV/HCV testing, STI screening, and pregnancy testing when applicable, with follow-up frequencies detailed by risk group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},405232,1790910248,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":24,"preview_page_count":4},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Long-Acting Injectable (LAI) PrEP Implementation Guide  \nComparing LAI PrEP Options  \nCAB-LA  \nApproved 2021  \nLEN  \nApproved 2025  \nAdministration  \nIM injection every 2 months  \n(1 injection per visit)  \nSC injections every 6 months  \n(2 injections per visit)  \nApproved for Common Adverse Events  \nAnyone vulnerable to HIV through sex  \nInjection site reactions  \nInitiation and Maintenance Dosing  \nCAB-LA (600 mg IM)  \nInitiation  \nMaintenance (every 2 months)  \nMonth 1 Month 2 Month 4 Month 6 Month 8  \n Each long-acting dose given as one 3.0 mL injection  Oral lead-in is optional in cases of tolerability concerns  \n• 30 mg oral CAB for 28 days  \n• Injections start same day or within 3 days of last oral dose  \nLEN (927 mg SC)  \nInitiation  \nMaintenance (every 6 months)  \nDay 1 Day 2  \n +600 mg oral  +600 mg oral  \n LEN  LEN  \nEach long-acting dose given as  \ntwo 1.5 mL injections  \nMonth 6  \n Oral lead-in on days 1 and 2 is required to reach protective LEN levels  \nIdeally, PrEP should be initiated as soon as possible for individuals who are likely to be exposed to HIV. However, logistical barriers like prior authorization requirements may delay initiation of LAI PrEP. If delays in starting injections are anticipated, offer oral PrEP for HIV prevention in the interim.  \n\n| \u003Cbr>Navigating Missed Doses\u003Cbr>If delays are anticipated...\u003Cbr>CAB-LA\u003Cbr>LEN\u003Cbr>• Start 30 mg CAB PO daily 2 months after last injection for up to 2 months\u003Cbr>• Tenofovir-based oral PrEP may be used instead (preferred if injections delayed > 2 months)\u003Cbr>• Resume injections on last day of oral dosing or within 3 days of last oral dose\u003Cbr>• Start 300 mg LEN PO once weekly 26 to 28 weeks after last injection for up to 6 months\u003Cbr>• Resume injections within 7 days of last oral dose |  |\n| --- | --- |\n| If CAB-LA injections are delayed\u003Cbr>> 7 days without oral bridging:\u003Cbr>• Test for HIV and resume if negative\u003Cbr>• Schedule according to  | \u003Cbr>Resume Regular Schedule\u003Cbr>Missed Injection \\# Injection 2 Injection 3+\u003Cbr>Time since last injection ≤ 2 months ≤ 3 months\u003Cbr>Repeat Initiation Dosing\u003Cbr>Injection 2 Injection 3+\u003Cbr>> 2 months > 3 months |\n| \u003Cbr>IAS-USA recommends CAB patients have a 1-month supply of tenofovir-based oral PrEP in case injections are delayed by > 7 days. |  |\n| If > 28 weeks have passed since last LEN injection without oral bridging, repeat initiation with oral lead-in. |  |\n\n\n| | ©2026 PRIME™ Education, LLC. All Rights Reserved.\u003Cbr>This activity is provided by PRIME Education. There is no fee to participate.\u003Cbr>This program has been supported by an independent educational grant from Gilead Sciences, Inc. | [primeinc.org](primeinc.org) |\n| --- | --- | --- |\n\n1  \n\n| \u003Cbr>Baseline and Follow-Up Laboratory Testing for Patients on LAI PrEP\u003Cbr>CDC IAS-USA |  |\n| --- | --- |\n| Baseline HIV testing\u003Cbr>Follow-up HIV testing\u003Cbr>At injection appointments | \u003Cbr>Lab-based Ag/Ab (4th or 5th gen) + HIV RNA on blood samples (oral fluid tests not appropriate)\u003Cbr>If HIV RNA testing is not available, repeat Ag/Ab testing 1 month after initiating PrEP\u003Cbr>Lab-based Ag/Ab only for LEN\u003Cbr>Lab-based Ag/Ab + HIV RNA for CAB-LA\u003Cbr>Lab-based Ag/Ab only for both CAB-LA and LEN |\n| HAV IgGHBV\u003Cbr>HCV IgG\u003Cbr>STI screening\u003Cbr>Pregnancy testing\u003Cbr>if applicable | \u003Cbr>Not mentioned\u003Cbr>Baseline only if switching from oral PrEP\u003Cbr>(HBsAg + HBsAb + anti-HBc)\u003Cbr>Baseline then Q6 months only for MSM, transgender women, PWID\u003Cbr>Baseline only for MSM, PWID who are not immune Baseline (HBsAg + HBsAb)\u003Cbr>Baseline then Q12 months\u003Cbr>Repeat Q3 to 6 months for MSM, PWID who use substances during sex\u003Cbr>3-site (genital, rectal, throat) chlamydia/gonorrhea NAAT + syphilis at baseline then Q6 months\u003Cbr>Repeat Q3 to 4 months for MSM, transgender women\u003Cbr>Baseline Baseline then Q3 to 4 months |\n\nCounseling Individuals Who Are Starting LAI PrEP  \nEducate about the importance of taking PrEP as prescribed and time needed for PrEP to be fully protective:  \n• CAB-LA: 7 days after first injectio","cbCaib4CCznoQTDZ","https://ap.wps.com/l/cbCaib4CCznoQTDZ","pdf",354661,"English","# Comparing LAI PrEP Options\n# Administration\n## Initiation and Maintenance Dosing\n# Navigating Missed Doses\n# Baseline and Follow-Up Laboratory Testing for Patients on LAI PrEP\n# Counseling Individuals Who Are Starting LAI PrEP\n# Considerations for Designing LAI PrEP Workflows\n# References","[{\"question\":\"How do CAB-LA and LEN differ in dosing frequency and injection schedule?\",\"answer\":\"CAB-LA is administered as an IM injection every 2 months (1 injection per visit). LEN is given as SC injections every 6 months (2 injections per visit).\"},{\"question\":\"What should be done if LAI PrEP injections are delayed?\",\"answer\":\"If delays are anticipated, offer oral PrEP as interim bridging. For CAB-LA, HIV testing is recommended when oral bridging is not used for more than 7 days, and injections are resumed based on the last injection timing; for LEN, repeat initiation with an oral lead-in is recommended if too much time has passed since the last injection.\"},{\"question\":\"What laboratory tests are required at baseline and during follow-up for patients on LAI PrEP?\",\"answer\":\"Baseline and follow-up HIV testing are required at injection appointments, with lab-based Ag/Ab and, for CAB-LA, HIV RNA testing using blood samples. Additional baseline screening includes HAV/HBV/HCV testing, STI screening, and pregnancy testing when applicable, with follow-up frequencies detailed by risk group.\"}]","Long-Acting Injectable (LAI) PrEP Implementation Guide - Dosing, Labs, and Workflow | PDF",1790555530]